UNASSIGNED: @entity735 are one of the characteristic adverse events associated with @entity11730 chemotherapy. In this retrospective study, we investigated the frequency and outcome of @entity735 associated with @entity11730 chemotherapy in @entity356 @entity1 . This retrospective study included 75 advanced @entity356 @entity1 who received @entity11730 monotherapy between January 2014 and December 2015. We retrospectively evaluated the frequency, Grade, and @entity735 . @entity735 were observed in 16 @entity1 (21%). The median time of onset was 3(range, 1-8)months. Grade 2 @entity735 , eye discharge, and @entity2024 were reported in 14, 8, and 4 @entity1 , respectively. Artificial tears, @entity11074 eye-drops, and both of these treatments were used in 7, 1, and 8 @entity1 , respectively. Ophthalmologic examination was performed for 3 @entity1 . No delay or reduction of @entity11730 therapy was required for the @entity735 . @entity735 associated with @entity11730 therapy in @entity356 @entity1 did not affect treatment if managed properly using eye drops.

[Eye Disorders Associated with XXXX Chemotherapy in @entity356 @entity1 ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity11730 :: ('5707', 'Gene') :: ['S-1'] @entity735 :: ('MESH:D005124', 'Disease') :: ['watering eyes', 'treatment of eye disorders', 'eye disorders', 'Eye disorders'] @entity11074 :: ('MESH:D005469', 'Chemical') :: ['fluorometholone'] @entity2024 :: ('MESH:D003231', 'Disease') :: ['conjunctivitis'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer']
@entity11730 :: (5707,Gene) :: ['S-1']
